BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/28/2020 2:46:56 PM | Browse: 883 | Download: 2054
 |
Received |
|
2020-02-03 23:49 |
|
Peer-Review Started |
|
2020-02-03 23:49 |
|
First Decision by Editorial Office Director |
|
2020-02-27 03:16 |
|
Return for Revision |
|
2020-02-27 03:16 |
|
Revised |
|
2020-05-24 22:06 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-06-17 09:16 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-06-17 20:53 |
|
Articles in Press |
|
2020-06-17 20:53 |
|
Edit the Manuscript by Language Editor |
|
2020-07-07 03:30 |
|
Typeset the Manuscript |
|
2020-07-28 07:31 |
|
Publish the Manuscript Online |
|
2020-07-28 14:46 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Friederike Cordes, Dirk Foell, John Nik Ding, Georg Varga and Dominik Bettenworth |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Friederike Cordes, MD, Doctor, Doctor, Department of Medicine B for Gastroenterology and Hepatology, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster D-48149, Germany. annafriederike.cordes@ukmuenster.de |
| Key Words |
Janus kinase; Signal transducer and activator of transcription; JAK/STAT pathway; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; JAK/STAT inhibition; Tofacitinib |
| Core Tip |
The pan-Janus kinase (JAK)-inhibitor tofacitinib is efficacious in patients with active ulcerative colitis (UC) but not Crohn’s disease (CD), which hints at different contribution of JAK-signaling in both entities. In this review available data on differential JAK/signal transducer and activator of transcription (STAT)-signaling in UC and CD were analyzed. Literature review identified differential cell-subset specific JAK/STAT-signaling including increased T-cell-associated STAT1 signaling in CD and STAT6 signaling in UC, while in myeloid cells inflammatory STAT1 was increased in UC compared with CD indicating a less inflammatory role of myeloid cells in CD. Development of JAK/STAT-inhibitors with specific targeting of associated inflammatory pathways might further improve efficacy and safety profiles of this drug class. |
| Publish Date |
2020-07-28 14:46 |
| Citation |
Cordes F, Foell D, Ding JN, Varga G, Bettenworth D. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease. World J Gastroenterol 2020; 26(28): 4055-4075 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i28/4055.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i28.4055 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
